Mirati Therapeutics reports Q3 EPS ($1.38), consensus ($1.25)
Reports Q3 revenue $988,000, consensus $210,000. Reports cash, cash equivalents, and short-term investments were $454.2M at September 30 compared to $222.8M at December 31, 2018. The company said, "The recent data presented demonstrate that MRTX849 treatment can result in clinical responses at well tolerated doses. We believe that MRTX849 clinical combinations, including the combination of MRTX849 with TNO155 in our collaboration with Novartis, will significantly increase the eligible patient population. We continue to expand and accelerate our KRAS programs and expect to continue expanding our team, including the addition of commercial talent so that we are ready to deliver our novel cancer therapies to the patients most in need."